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http://dx.doi.org/10.1016/j.stemcr.2016.07.018SUMMARYGermline mutations in BRAF cause cardio-facio-cutaneous syndrome (CFCS), whereby 40% of patients develop hypertrophic cardio-
myopathy (HCM). As the role of the RAS/MAPK pathway in HCM pathogenesis is unclear, we generated a human induced plurip-
otent stem cell (hiPSC) model for CFCS from three patients with activating BRAF mutations. By cell sorting for SIRPa and CD90, we
generated a method to examine hiPSC-derived cell type-specific phenotypes and cellular interactions underpinning HCM. BRAF-
mutant SIRPa+/CD90 cardiomyocytes displayed cellular hypertrophy, pro-hypertrophic gene expression, and intrinsic calcium-
handling defects. BRAF-mutant SIRPa/CD90+ cells, which were fibroblast-like, exhibited a pro-fibrotic phenotype and partially
modulated cardiomyocyte hypertrophy through transforming growth factor b (TGFb) paracrine signaling. Inhibition of TGFb or
RAS/MAPK signaling rescued the hypertrophic phenotype. Thus, cell autonomous and non-autonomous defects underlie HCM
due to BRAF mutations. TGFb inhibition may be a useful therapeutic option for patients with HCM due to RASopathies or other
etiologies.INTRODUCTION
The RASopathies are developmental disorders caused by
mutations in the RAS/MAPK pathway, characterized by
pleomorphic developmental defects including facial dys-
morphism, short stature, neurocognitive delay, and cardiac
defects. One of the commonest cardiac manifestations is
hypertrophic cardiomyopathy (HCM) (Tartaglia and Gelb,
2010).
HCM is defined as thickening of themyocardium that oc-
curs in the absence of an underlying insult, usually result-
ing from mutations in various genes encoding sarcomeric
components. Histologically, there is cardiomyocyte (CM)
enlargement and increased fibrosis. HCM is molecularly
characterized by upregulation of a fetal gene program
including increased expression of atrial natriuretic peptide
(ANP) and brain natriuretic peptide (BNP), often with dys-
regulated calcium handling (Konno et al., 2010). About
70% of patients with HCM develop obstruction, while
other complications include arrhythmias, heart failure,
and sudden cardiac death (Harris et al., 2006).
The role of RAS/MAPK signaling in cardiac hypertrophy
remains unclear. Cardiac-restricted overexpression of
Mek1 caused compensated hypertrophy with increased
cardiac function (Bueno et al., 2000). In addition,Stem Cell Rep
This is an open access article under the CErk1/Erk2+/micewere not protected frompressure over-
load or agonist stimulation (Purcell et al., 2007). However,
oncogenic Hras over-expression led to pathological hyper-
trophy with fibrosis and calcium-handling defects (Hunter
et al., 1995; Zheng et al., 2004), and dominant-negative
Raf1 overexpression prevented pressure overload-induced
cardiac hypertrophy (Harris et al., 2004). Some suggest
that the pathological effects of RAS and RAF signaling
may not be exclusively mediated by downstream MAPK
signaling but rather by cross-activation of other pathways
(Heineke and Molkentin, 2006).
Mice expressing the RASopathy Raf1L613Vallele developed
HCM, rescued by MEK inhibition (Wu et al., 2011). How-
ever, mice with activating BRAF mutations did not exhibit
pathological cardiac remodeling (Andreadi et al., 2012; Uro-
sevic et al., 2011). Thus, the pathogenesis of HCM in cardio-
facio-cutaneous syndrome (CFCS), whereby 75% of cases
have germline BRAF mutations (Rodriguez-Viciana et al.,
2006) and 40% develop HCM (Armour and Allanson,
2008), is unclear. To study this, we generated an hiPSC
model of CFCS and developed a method to examine
hiPSC-derived cell type-specific phenotypes and cellular in-
teractions underpinning HCM by cell sorting based on
SIRPa and CD90 expression. We show that purified CMs
derived from hiPSCs harboring the CFC-causing T599R ororts j Vol. 7 j 355–369 j September 13, 2016 j ª 2016 The Authors. 355
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Differentiation and Purification
of hiPSC-derived CMs
(A) Sequencing confirmed the heterozy-
gous BRAF T599R (BRAF1) and the Q257R
mutations (BRAF2, BRAF3) in hiPSCs. Red
asterisks note the positions of the BRAF
mutations.
(B) Cardiac differentiation protocol. hiPSCs
were exposed to a series of cytokines to
induce cardiogenesis. CMs were sorted for
purification after day 25.
(C) Cell-sorting strategy to purify SIRPa+/
CD90 cells and SIRPa/CD90+ cells.
(D) Staining for cTNT demonstrated purifi-
cation of >95% CMs after sorting for SIRPa+/
CD90 cells.
See also Figures S1 and S2.Q257R BRAF mutations display cellular hypertrophy and
intrinsic calcium-handling defects. In addition, fibroblast-
like cells (FLCs) derived from BRAF-mutant hiPSCs exhibit
pro-fibrotic behavior and modulate the hypertrophic
phenotype through paracrine transforming growth factor
b (TGFb) signaling. Both TGFb and RAS/MAPK inhibition
rescue the hypertrophic phenotype.RESULTS
Generation and Purification of Wild-Type and
BRAF-Mutant iPSC-Derived CMs
hiPSCs were generated from dermal fibroblasts from three
unrelated patients with CFCS. Patient 1 (BRAF1) harbored
the known BRAF T599Rmutation (Yoon et al., 2007), which
alters the activation segment of the kinase domain and is ki-
nase activating (Wan et al., 2004). Patients 2 and 3 (BRAF2,
BRAF3) harbored BRAF Q257R mutations, the commonest
CFCS mutation, which alters the cysteine-rich domain of
the conserved region 1 (CR1) and is also kinase activating
(Rodriguez-Viciana et al., 2006). Patients 1 and 2 displayed
HCM while patient 3 did not. Wild-type (WT) hiPSC lines
generated from three unrelated healthy individuals served
as controls. DNA sequencing confirmed the heterozygous356 Stem Cell Reports j Vol. 7 j 355–369 j September 13, 2016BRAFmutations in mutant hiPSC lines (Figure 1A). Mutant
lines had normal karyotypes, and pluripotency was con-
firmed with immunofluorescence, gene expression, and
tri-lineage differentiation assays (Figure S1).
hiPSCs were differentiated along a cardiogenic lineage as
3D embryoid bodies (EBs) using a modification of an estab-
lished protocol (Yang et al., 2008) (Figure 1B). In addition
to three WT hiPSC lines, two clones from each mutant
hiPSC line were used in subsequent experiments (Table
S1). Spontaneous beating was observed between days 10
and 12 of differentiation. To detect potential molecular
defects intrinsic to CMs and non-CMs, we purified these
populations separately using flow cytometry based on their
expression of SIRPa, a CMmarker (Dubois et al., 2011), and
CD90, a marker that labels the majority of non-CMs
derived from PSCs (Dubois et al., 2011; Kisselbach et al.,
2009). SIRPa+/CD90 cells were >95% CMs based on car-
diac troponin T (cTNT; TNNT2) expression (Figures 1C
and 1D). Expression of the cardiac-specific genes ANP,
MYH6, and TNNT2 was restricted to the SIRPa+ cells. Re-
cultured SIRPa+/CD90 cells formed synchronous mono-
layers that beat spontaneously and homogeneously ex-
pressed cTNT. While differentiation efficiency was variable
among lines, no reproducible difference was observed be-
tween WT and BRAF-mutant lines (Figure S2).
BRAF-Mutant CMs Display a Cellular Hypertrophy
Phenotype
To determine whether BRAF-mutant CMs displayed hyper-
trophy, we dissociated whole EBs andmeasured the cellular
area of re-plated single cTNT+ cells. Across lines, BRAF-
mutant CMs were on average more than three times larger
than WT CMs (p < 0.0001) (Figure 2A). Using flow cytom-
etry to analyze forward scatter (FSC) as a surrogate of 3D
cellular size, BRAF-mutant CMs were also larger than WT
CMs (Figure S3). Increased sarcomeric organization, a hall-
mark of cardiac hypertrophy (Aoki et al., 2000) demon-
strated by a striated cTNT staining pattern, was apparent
in BRAF-mutant CMs (58%) compared with WT (16%;
p < 0.0001). The most pronounced sarcomere organization
was observed in severely hypertrophied BRAF-mutant CMs
(Figure 2B). Upregulation of a fetal gene program, classi-
cally observed in HCM (Kuwahara et al., 2003), was also
noted in purified BRAF-mutant CMs, which displayed >5-
fold and >6-fold increased expression of ANP and BNP,
respectively, compared with WT (p < 0.0001), as well as
a >8-fold increased b-myosin heavy chain (MYH7) to
a-myosin heavy chain (MYH6) ratio (p = 0.078) (Figure 2C).
Purified BRAF-Mutant CMs Display Altered Calcium
Handling
Dysregulation of calcium (Ca2+) handling has been
observed in many HCM models (Molkentin, 2004),
including an hiPSC model of familial HCM (Lan et al.,
2013). In purified BRAF-mutant CMs, phospholamban
(PLN) expression was significantly decreased (p = 0.016)
(Figure 2C) with a trend toward increased SERCA2a expres-
sion (data not shown). To assess whether BRAF-mutant
CMs had impaired Ca2+ handling, we analyzed Ca2+ tran-
sients in paced cells. Compared with WT, BRAF-mutant
CMs displayed a significantly increased frequency of irreg-
ular transients (28% versus 6%, p < 0.0001), defined as an
extra Ca2+ transient peak during the decay of the previous
transient, indicating unstable Ca2+ release from the sarco-
plasmic reticulum (SR). A small percentage of BRAF-mutant
CMs also displayed discordance between the timing of
electrical stimulation and resulting Ca2+ transient, further
indicating underlying instability (Figure 3A).
Consistent with increased Ca2+ release observed in
mouse hearts overexpressing SERCA2a (Baker et al.,
1998), BRAF-mutant CMs also displayed increased Ca2+
release from the SR, as reflected by increased transient
amplitude compared with WT (3.6 a.u. versus 2.6 a.u.,
p < 0.0001) (Figure 3B). Exposure to the ryanodine receptor
activator caffeine revealed that BRAF-mutant CMs con-
tained increased stored Ca2+ compared with WT (6.2 a.u.
versus 4.5 a.u., p < 0.001) (Figure 3C), similar to observa-
tions during early cardiac hypertrophy (Delbridge et al.,
1997; Sipido et al., 2000). Our results demonstratethat BRAF-mutant CMs possess intrinsic defects in Ca2+
handling, representative of early-stage HCM.
Multiple BRAF-Mutant Cell Types Display Activation
of the RAS/MAPK Pathway
To assess RAS/MAPK pathway activation, we analyzed ERK
activation basally and after stimulation with epidermal
growth factor (EGF) or angiotensin II (AngII). ERK activa-
tion was sustained over time in BRAF-mutant hiPSCs
compared with WT (Figure S5A). In contrast, ERK activa-
tion was not increased in BRAF-mutant CMs compared
with WT CMs (Figure 4A).
The contribution of non-CMs as crucial to the hypertro-
phic response has been increasingly recognized (Fujiu and
Nagai, 2014). To address whether BRAF-mutant non-CMs
display activation of the RAS/MAPK pathway, we purified
the SIRPa/CD90+ population (Figure 1C). CD90 labeled
the majority of non-CM cells across hiPSC lines (Fig-
ure S2C). To investigate the specific cell type to which the
CD90+ cells are most closely related, we performed gene-
expression profiling. CD90+ cells did not express markers
of stem cells (REX1) or endothelial cells (CD31, CDH5),
but robustly expressed three fibroblast markers (VIM,
COL1A2, andDDR2), which were also expressed by human
fetal SIRPa/CD90+ cells (Figure S4A).Within cardiac tissue,
fibroblasts exclusively expressDDR2 (Camelliti et al., 2005).
In addition, hiPSC-derived CD90+ cells displayed a spindle-
shaped morphology similar to fibroblasts (Figure S4B).
Thus, we henceforth refer to CD90+/SIRPa cells as FLCs.
BRAF-mutant FLCs displayed increased ERK activation
compared with WT FLCs, with significantly larger activa-
tion in the basal state (1.8 a.u. versus 0.9 a.u., p = 0.0059)
(Figure 4B). Importantly, activation of AKT was not
observed in BRAF-mutant CMs or FLCs (Figures S5B and
S5C), distinct from AKT/mTOR involvement in a related
RASopathy syndrome due to PTPN11 mutations (Marin
et al., 2011), but similar to findings inmice withmutations
in RAF isoforms (Wu et al., 2011).
BRAF-Mutant FLCs Are Pro-fibrotic and Influence the
Hypertrophic Phenotype
To investigate whether activated BRAF-mutant FLCs were
modulating the CM hypertrophic phenotype, we co-
cultured purified WT CMs along with purified WT or
BRAF-mutant FLC populations (Figure 5A). Strikingly, the
cellular area of WT CMs doubled when co-cultured with
BRAF-mutant FLCs compared with WT FLCs (p < 0.0001)
(Figures 5B and 5C).
Next, we examined whether BRAF-mutant FLCs dis-
played behavior similar to activated fibroblasts in the
setting of fibrosis. Compared with WT, BRAF-mutant
FLCs were hyperproliferative (15% versus 7%, p = 0.03)
(Figure 5D). BRAF-mutant FLCs also expressed significantlyStem Cell Reports j Vol. 7 j 355–369 j September 13, 2016 357
Figure 2. BRAF-Mutant hiPSC-Derived CMs Display Cellular Hypertrophy
(A) Increased cellular area of cTNT+ BRAF-mutant CMs (n = 35–54 per line; three independent experiments each) compared with WT
(n = 22–58 per line; three independent experiments each). Box-and-whisker plots show the median to the first and third quartiles and the
minimum and maximum values. ****p < 0.0001 for WT versus all individual BRAF lines. Scale bars, 200 mm.
(B and C) Data are presented as mean ± SEM for compiled WT versus BRAF cell lines along with compiled statistical significance results. To
the right of the compiled data, data points representing results for individual patient lines are presented, as shown in the accompanying
legend. Filled symbols indicate lines with identical mutation (Q257R). (B) Increased percentage of striated sarcomeres in cTNT+ BRAF-
mutant CMs (n = 371) compared with WT (n = 579). Data represent three biological (WT1, 2, 3; BRAF1, 2, 3) and three technical replicates
(compiled ****p < 0.0001; WT versus BRAF1, 2, or 3 all p < 0.0001). Scale bars, 200 mm. (C) Increased expression of hypertrophy-
associated genes and decreased PLN expression in BRAF-mutant CMs (n = 6) compared with WT (n = 5). Data represent three biological
(WT1, 2, 3; BRAF1, 2, 3) and three technical replicates. For ANP expression, compiled ****p < 0.0001; WT versus BRAF1 p = 0.0001,
WT versus BRAF2 p = 0.6644 (not significant), WT versus BRAF3 p = 0.0001. For BNP expression, compiled ***p < 0.001; WT
versus BRAF1 p = 0.0001, WT versus BRAF2 p = 0.9969 (not significant), WT versus BRAF3 p = 0.0001. For MYH7/MYH6 expression, compiled
**p = 0.0078; WT versus BRAF1 p = 0.0073, WT versus BRAF2 p = 0.9999 (not significant), WT versus BRAF3 p = 0.0005. For PLN expression,
compiled *p = 0.016; WT versus BRAF1 p = 0.3780 (not significant), WT versus BRAF2 p = 0.0750 (not significant), WT versus
BRAF3 p = 0.0210. See also Figure S3.
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Figure 3. Purified BRAF-Mutant CMs
Display Dysregulated Calcium Handling
Data are presented as mean ± SEM for
compiled WT versus BRAF cell lines along
with compiled statistical significance re-
sults and results for individual patient lines
(see Figure 2 legend). Data represent three
biological (WT1, 2, 3; BRAF1, 2, 3) and six
technical replicates.
(A) Purified BRAF-mutant CMs (n = 123)
displayed increased frequency of irregular
Ca2+ transients compared with WT (n = 74)
and a discordance between the timing of
stimulation and the resulting Ca2+ transient.
Compiled ****p < 0.0001; WT versus
BRAF1 p = 0.9908 (not significant), WT
versus BRAF2 p = 0.0001, WT versus
BRAF3 p = 0.0001.
(B) Increased Ca2+ transient amplitude in
purified BRAF-mutant CMs (n = 123)
compared with WT (n = 74). Compiled
****p < 0.0001; WT versus BRAF1 p =
0.0453, WT versus BRAF2 p = 0.0006, WT
versus BRAF3 p = 0.0001.
(C) Purified BRAF-mutant CMs (n = 41)
possessed increased stored Ca2+ content
compared with WT (n = 28) as assessed by
exposure to caffeine. Compiled ***p <
0.001; WT versus BRAF1 p = 0.0001, WT
versus BRAF2 p = 0.774 (not significant), WT
versus BRAF3 p = 0.0015.increased levels of fibrosis-associated genes, including
TGFb1 (p = 0.002), periostin (POSTN) (p = 0.01), connective
tissue growth factor (CTGF) (p = 0.002), and collagen type I
(COL1A2) (p = 0.003), and a trend toward increased expres-
sion of endothelin-1 (ET-1) (p = 0.07) (Figure 5E). Thus, the
BRAF-mutant FLCs displayed a pro-fibrotic phenotypewith
upregulation of several TGFb pathway members, suggest-
ing a role for TGFb signaling inmediating the hypertrophic
response.
BRAF-Mutant FLCs Influence CM Hypertrophy
through Paracrine TGFb1 Secretion
To determine whether the effect of the BRAF-mutant FLCs
on the hypertrophic phenotype was mediated by a para-
crine effect, we cultured purified WT and BRAF-mutant
CMs with conditioned media from purified WT and
BRAF-mutant FLCs (Figure 6A). Remarkably, when WT
CMs were exposed to BRAF-mutant FLC conditioned me-dia, their cellular area nearly doubled (p < 0.0001) and
was similar to that of BRAF-mutant CMs exposed to
BRAF-mutant FLC conditioned media. Exposure to BRAF-
mutant FLC conditioned media also resulted in signifi-
cantly increased ANP expression in WT CMs (p = 0.03).
When BRAF-mutant CMs were cultured with WT FLC
conditioned media, their cellular area decreased by 30%
(p = 0.008) (Figures 6B–6D). Thus, we concluded that
BRAF-mutant FLCs were modulating CM hypertrophy
through a paracrine mechanism.
TGFb has been implicated in signaling between fibro-
blasts and CMs, mediating hypertrophic growth (Gray
et al., 1998; Koitabashi et al., 2011). Using an ELISA, we
found that the amounts of active and total TGFb protein
secreted by BRAF-mutant FLCs were increased compared
with those from WT cells. No difference in TGFb1 gene
expression or secreted TGFb protein level was observed be-
tween BRAF-mutant and WT CMs (Figures S6A–S6C).Stem Cell Reports j Vol. 7 j 355–369 j September 13, 2016 359
Figure 4. RAS/MAPK Pathway Activation in
Purified hiPSC-Derived CMs and FLCs
Data are presented as mean ± SEM for
compiled WT versus BRAF cell lines along with
compiled statistical significance results for
WT versus BRAF at each time point and results
for individual patient lines (see Figure 2
legend). Data represent three biological
(WT1, 2, 3; BRAF1, 2, 3) and two technical
replicates. Cells were stimulated with AngII
for 0 or 15 min.
(A) BRAF-mutant CMs (n = 8) did not have
increased pERK activation compared with WT
(n = 6). At 0 min: compiled p = 0.2944 (not
significant [n.s.]); WT versus BRAF1 p =
0.9799, WT versus BRAF2 p = 0.2347, WT
versus BRAF3 p = 0.7139 (all not significant).
At 15 min: compiled p = 0.6633 (not signifi-
cant); WT versus BRAF1 p = 0.9982, WT versus
BRAF2 p = 0.7438, WT versus BRAF3 p =
0.9897 (all not significant).
(B) BRAF-mutant FLCs (n = 8) displayed
increased activation of pERK compared with
WT (n = 6). At 0 min: compiled **p = 0.0059;
WT versus BRAF1 p = 0.0159, WT versus
BRAF2 p = 0.0001, WT versus BRAF3 p =
0.1541 (not significant). At 15 min: compiled
p = 0.1476 (not significant); WT versus
BRAF1 p = 0.5359, WT versus BRAF2 p = 0.2032, WT versus BRAF3 p = 0.9781 (all not significant).
All values normalized to GAPDH. WT and BRAF lanes were run on the same gel but were non-contiguous. See also Figures S4 and S5.To verify whether the paracrine effect of the BRAF-
mutant FLCs was mediated by increased TGFb secretion,
we pre-incubated conditioned media with a pan-TGFb
neutralizing antibody (TGFb-NA). TGFb-NA-treated condi-
tioned media from BRAF-mutant FLCs failed to produce a
hypertrophic effect on WT or BRAF-mutant CMs (p =
0.01), and resulted in significantly decreased expression
of BNP in BRAF-mutant CMs (p = 0.008) (Figures 6B, 6C,
and 6E). Thus, we concluded that TGFb signaling was
necessary for the hypertrophy observed in the BRAF-
mutant CMs.
To determine whether TGFb signaling was sufficient for
the induction of CM hypertrophy, we incubated CMs
with recombinant human TGFb (rhTGFb). Upon exposure
to rhTGFb, the cellular area of BRAF-mutant and WT CMs
significantly increased (p < 0.0001 and p = 0.03, respec-
tively) (Figure S6D). Exposure of purified CMs to TGFb-NA
demonstrated no significant change in their cellular area,
further implicating the source of increased TGFb as derived
from BRAF-mutant FLCs rather than BRAF-mutant CMs.
Together, our results reveal non-CM autonomous defects
in BRAF-mutant FLCs, which contribute to the hypertro-
phic phenotype observed in BRAF-mutant CMs through
increased TGFb signaling.360 Stem Cell Reports j Vol. 7 j 355–369 j September 13, 2016Activation of the RAS/MAPK Pathway Induces the
Hypertrophic Phenotype
To test whether MEK inhibition could ameliorate the hy-
pertrophic phenotype in hiPSC-derived CMs, we exposed
a mixed population of CMs and non-CMs to the MEK in-
hibitor U0126. While U0126 treatment had no effect on
WT CM cellular area, the cellular area of BRAF-mutant
CMs was reduced by 36% (p < 0.0001) to a size not signifi-
cantly different from WT (Figure 7A), likely due to MEK
inhibition affecting BRAF-mutant FLCs. In addition, treat-
ment of purified BRAF-mutant CMs in the absence of FLCs
with U0126 normalized their intrinsic Ca2+-handling
defects, including decreasing the percentage of irregular
transients and SR Ca2+ content to levels not significantly
different from WT (Figures 7B and 7C).
To document further that the CM hypertrophy was due
to BRAF gain of function, we exposed purified WT and
BRAF-mutant CMs to conditioned media from WT or
BRAF-mutant FLCs that had or had not been treated with
the BRAF inhibitor GDC-0879 (GDC). Both WT and
BRAF-mutant CMs displayed significantly reduced cellular
area after exposure to conditioned media taken from
BRAF-mutant FLCs treated with GDC (p = 0.01 and p =
0.0006, respectively) (Figures S7A and S7B).
Figure 5. BRAF-Mutant FLCs Influence
the Hypertrophic Phenotype
(A) Schematic of co-culture experiment. WT
CMs and WT and BRAF-mutant FLCs (Fib-
like) were sorted from EBs and re-cultured
together.
(B) Representative images of co-culture
treatment groups stained with cTNT. Scale
bars, 200 mm.
(C) Quantification of cellular area as de-
picted in (B). WT CMs became significantly
larger upon co-culture with BRAF-mutant
Fib-like cells (n = 67) compared with co-
culture with WT Fib-like cells (n = 62)
(****p < 0.0001). Box-and-whisker plots
show the median to the first and third
quartiles and the minimum and maximum
values. Data represent two biological (WT2,
3; BRAF1, 2) and three technical replicates.
(D) Increased proliferation rate of purified
BRAF-mutant Fib-like cells (n = 3) compared
with WT (n = 2) as demonstrated by
increased staining for Ki67 by flow cy-
tometry (*p = 0.03). Data represent two
(WT2, 3) or three (BRAF1, 2, 3) biological
and two technical replicates. Data are pre-
sented as means ± SEM.
(E) Purified BRAF-mutant Fib-like cells ex-
pressed increased levels of fibrosis-associ-
ated genes compared with WT; TGFb1 (BRAF
n = 24, WT n = 18, **p = 0.002), POSTN
(BRAF n = 15, WT n = 3, *p = 0.01), CTGF
(BRAF n = 18, WT n = 12, **p = 0.002),
COL1A2 (BRAF n = 24, WT n = 15, **p =
0.003), and ET-1 (BRAF n = 15, WT n = 8, p =
0.07, not significant). Data represent three
biological (WT1, 2, 3; BRAF1, 2, 3) and three
technical replicates. Data are presented as
means ± SEM.To demonstrate whether activated BRAF was sufficient
to induce CM hypertrophy, we overexpressed BRAF
T599R cDNA in WT hiPSCs (WT-T599R). The presence
of mutant cDNA was confirmed by Sanger sequencing,
and increased expression of BRAF was confirmed by
qPCR (Figure S7C). Compared with conditioned
media from WT FLCs expressing only an empty vector,
exposure to conditioned media from WT-T599R FLCs
induced significantly increased cellular area (p = 0.02)
and expression of ANP and BNP in WT CMs. Expression
of those genes reached levels similar to those observed
with BRAF-mutant CMs exposed to BRAF-mutant
FLC conditioned media (Figures S7D–S7F). The largest
enlargement in cellular area was observed in WT-
T599R CMs exposed to WT-T599R FLC conditioned me-
dia (p < 0.0001). These data suggest that overactivationof BRAF and the RAS/MAPK pathway can engender CM
hypertrophy.DISCUSSION
In this study we have shown that activating BRAF muta-
tions leading to increased RAS/MAPK pathway signaling
induce a hypertrophic phenotype in hiPSC-derived CMs.
While BRAF-mutant CMs display intrinsic defects in
Ca2+ handling, several aspects of their phenotype require
paracrine TGFb secretion by activated, pro-fibrotic BRAF-
mutant FLCs. Inhibition of TGFb or RAS/MAPK signaling
rescues the hypertrophic phenotype. Interestingly, while
patient 3 did not show clinical evidence of HCM, we de-
tected underlying defects indistinguishable from thoseStem Cell Reports j Vol. 7 j 355–369 j September 13, 2016 361
Figure 6. BRAF-Mutant FLCs Influence CM Hypertrophy through Paracrine TGFb1 Secretion
(A) Schematic of conditioned media experiment. WT and BRAF-mutant CMs and FLCs (Fib-like) were sorted from EBs and re-cultured
separately. After 4 days, CMs were exposed to Fib-like conditioned media.
(B) Representative images of treatment groups stained with cTNT. TGFb-NA indicates pre-incubation of Fib-like conditioned media with a
TGFb neutralizing antibody prior to CM exposure. Scale bars, 200 mm.
(C) Quantification of cellular area as depicted in (B). WT CMs exposed to BRAF-mutant Fib-like conditioned media (n = 97) became
significantly enlarged compared with exposure to WT Fib-like conditioned media (n = 91) (****p < 0.0001). This effect was prevented by
pre-incubation with TGFb-NA (n = 92). Cellular hypertrophy in BRAF-mutant CMs (n = 86) was significantly reduced upon incubation
with WT Fib-like conditioned media (n = 88) (**p = 0.008), or pre-incubation of BRAF-mutant Fib-like conditioned media with TGFb-NA
(n = 134) (*p = 0.01). Box-and-whisker plots show the median to the first and third quartiles and the minimum and maximum values. ns,
not significant.
(D) WT CMs exposed to BRAF-mutant Fib-like conditioned media upregulated ANP (n = 3) compared with WT Fib-like conditioned media
(n = 3) (*p = 0.03). Data are presented as means ± SEM.
(legend continued on next page)
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Figure 7. Inhibition of MEK Reverses the Hypertrophic Phenotype in BRAF-Mutant CMs
(A) Dissociated EBs were treated with the MEK inhibitor U0126 and cellular area of cTNT+ cells quantified. Exposure to U0126 (n = 130)
significantly decreased the cellular area of BRAF-mutant CMs (n = 142) by 36% (****p < 0.0001), but had no significant effect (ns) on the
cellular area of WT CMs (n = 57). Box-and-whisker plots show the median to the first and third quartiles and the minimum and maximum
values. Scale bars, 200 mm.
(B and C) Purified BRAF-mutant CMs exposed to U0126 displayed (B) decreased prevalence of irregular transients (n = 34) (****p < 0.0001)
and (C) decreased SR Ca2+ content (n = 12) (***p < 0.001). Data are presented as means ± SEM. n.s., not significant. Data represent two
(WT2, 3) and three (BRAF1, 2, 3) biological and four technical replicates.
See also Figure S7.in patients 1 and 2, both diagnosed with HCM. Similar
subclinical pathology has been demonstrated in other
hiPSC models of HCM (Lan et al., 2013). However, it is
also possible that more complex factors active in 3D
multi-organ systems such as hemodynamic load, which
are inadequately modeled using the 2D hiPSC system,
may play a role in disease progression. We recently gener-(E) BRAF-mutant CMs exposed to BRAF-mutant Fib-like conditioned m
rescued upon exposure to conditioned media with TGFb-NA (n = 3) (*
like conditioned media (n = 3). Data represent three biological replica
two biological replicates (WT2, 3; BRAF1, 2) for TGFb-NA experiment
Three technical replicates were performed for all conditions. See alsoated a 3D human engineered cardiac tissue (hECT) model,
in which BRAF-mutant hECTs displayed increased twitch
force and contraction and relaxation rates, and a lower
excitation threshold compared with WT (Cashman et al.,
2016). In the future, these hECT models may be helpful
for investigating more complex factors such as tissue
perfusion, flow dynamics, and mechanical stress, toedia (n = 3) upregulated BNP expression (**p = 0.001), which was
*p = 0.008), to levels similar to those in WT CMs exposed to WT Fib-
tes (WT1, 2, 3; BRAF1, 2, 3) for conditioned media experiments, and
s.
Figure S6.
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enable higher-fidelity physiologic measurements of
muscle function.
Some aspects of the intrinsic CM phenotype we docu-
ment have been associated with enhanced cellular matura-
tion in culture, including organized sarcomeres and
increased cellular area (Yang et al., 2014). However,
matured stem cell-derived CMs develop into elongated
rods with myofibrils arranged parallel to the long axis of
the cell, and do not display the irregular, generalized
increase in cellular area that we observed. In addition,
immature derived CMs possess sophisticated excitation-
contraction coupling and do not display increased Ca2+
transient amplitude, irregularity, or increased SR Ca2+
stores upon maturation (Lundy et al., 2013). Although
genotype-specific influences on CM maturation may
contribute to the CM phenotype, the HCM phenotype
we observe in its totality cannot be attributed to them. In
addition, the variations in cardiac differentiation effi-
ciencies we document do not segregate WT and mutant
populations and are unrelated to CMmaturation, as SIRPa
expression is detected in stem cell-derived CMs between
days 7 and 8 of differentiation (Dubois et al., 2011).
Our data also reveal variability in behavior among hiPSC
lines (Figures 2, 3, and 4), often attributed to variations that
occur during re-programming (Toivonen et al., 2013) and
to distinct genetic backgrounds. This variability cannot
be attributed to a single cell line and is not replicated across
distinct experiments. To strengthen our conclusions, we
have utilized six independent patient samples and pro-
vided inhibitory and overexpression studies, which sup-
port our claims.
To date, hiPSC models for cardiac disease have utilized
mixed cell populations (Lan et al., 2013; Zanella et al.,
2014), obscuring possible contributions of neighboring
cells to the disease phenotype. Here, we developed an effec-
tive dual-purificationmethod to study cell interactions un-
derpinning human HCM. By combining CM and non-CM
markers, we increased hiPSC-derived CMpurity from <70%
(Dubois et al., 2011) to >95% while simultaneously purify-
ing the non-CM fraction. While CD90 is a well-described
marker for human fibroblasts (Kisselbach et al., 2009), it
has also been shown to label stem cells, lymphocytes, neu-
rons, and activated endothelial cells (Herrera-Molina et al.,
2013). As CM differentiation protocols direct mesodermal
lineage formation (Mummery et al., 2012), robust stem
cell differentiation intomany of these cell types is unlikely.
The expression of multiple fibroblast- and fibrosis-associ-
ated genes in CD90+ cells supports their likely identity
as FLCs.
The importance of the interaction between fibroblasts
and CMs in cardiac hypertrophy has been previously
demonstrated. In neonatal rat and mouse CMs, hyper-
trophy was dependent on exposure to fibroblasts or their364 Stem Cell Reports j Vol. 7 j 355–369 j September 13, 2016conditioned media, and was mediated by fibroblast para-
crine TGFb1 release (Fredj et al., 2005; Gray et al., 1998).
AngII induces a pro-fibrotic phenotype in fibroblasts, stim-
ulating proliferation, collagen synthesis, and extracellular
matrix proteins (Bouzegrhane and Thibault, 2002), medi-
ated by upregulation and secretion of various factors
including TGFb (Kawano et al., 2000). In vivo, the hyper-
trophic response to AngII treatment or pressure overload
was dependent on TGFb signaling (Kuwahara et al., 2002;
Schultz Jel et al., 2002). In these models, exogenous stimuli
were utilized to induce cardiac hypertrophy, a phenome-
non distinct from HCM. Here, we have shown in a human
HCM model due to elevated RAS/MAPK signaling that
paracrine TGFb signaling from FLCs to CMs directly stimu-
lates the hypertrophic response. Indeed, it has been shown
that AngII stimulates TGFb synthesis in cardiac fibroblasts
through activation of theMAPK substrate ELK-1 in humans
(Kawano et al., 2000). In a mouse model of familial HCM
due to aMHC mutations, cardiac fibrosis was mediated by
non-myocyte proliferation and TGFb signaling (Teekakiri-
kul et al., 2010). In this model, mutant CMs were shown
to activate the non-myocyte population, which then
contributed to fibrosis. The ability of activated fibroblasts
to directly stimulate cardiac hypertrophy, in addition to
their well-known role in fibrosis,may be conserved in other
etiologies of HCM, although the mechanism of fibroblast
activation may be different.
Inhibition of TGFb abolished the ability of BRAF-mutant
FLCs to induce CM hypertrophy, suggesting that TGFb in-
hibition may provide therapeutic benefit to CFCS patients
with HCM. Few pre-clinical and clinical studies have
demonstrated therapeutic efficacy of TGFb inhibition in
HCM. In mice with sarcomeric mutations, TGFb pathway
inhibition prior to or after the onset of HCM normalized
several pathological features, such as non-myocyte prolif-
eration, pro-fibrotic gene expression (Teekakirikul et al.,
2010), and interstitial fibrosis (Lim et al., 2001). In small
clinical studies, patients with existing HCM treated with
losartan exhibited improved diastolic function (Araujo
et al., 2005), decreased ventricular mass, and reduced
fibrosis (Shimada et al., 2013). These studies suggest a po-
tential therapeutic role for TGFb inhibition in HCM due
to various etiologies. Our work also directly implicates acti-
vation of the RAS/MAPK pathway in HCM, as inhibition of
MEK or BRAF rescued the hypertrophic phenotype while
overexpression of activated BRAF induced CM hypertro-
phy. While there has been no clinical trial conducted
to assess the effect of MEK inhibition on hypertrophy in
RASopathy patients, MEK inhibition has been associated
with an extensive side-effect profile in humans (Akinleye
et al., 2013). More work is necessary to determine whether
TGFb inhibition would be preferable to MEK inhibition in
the treatment of RASopathy-associated HCM, particularly
in patients with well-established disease with significant
fibrosis.
In summary, we have shown that activation of the RAS/
MAPK pathway leads to CM hypertrophy driven by CM
autonomous and non-autonomous defects. We describe a
potential therapeutic benefit of TGFb inhibition or RAS/
MAPK inhibition for HCM in CFCS patients, for which
no curative option exists. TGFb inhibition may find thera-
peutic efficacy in patients with HCM of various etiologies.EXPERIMENTAL PROCEDURES
hiPSC Generation and Maintenance
BRAF1 dermal fibroblasts were obtained from an 18-year-old female
with HCM. BRAF1 hiPSCs were generated using retroviral pMX-
based vectors encoding human OCT3/4, SOX2, KLF4, and c-MYC
as previously published (Carvajal-Vergara et al., 2010) with modifi-
cations. Retrovirus was added to fibroblasts 24 and 48 hr after
plating. After day 4 the medium was changed every 2 days, and
hESC-like colonies were isolated after 30 days. BRAF2 and BRAF3
dermal fibroblasts were obtained from a 13-year-old female with
HCMand a 2-year-oldmale without evidence of HCM, respectively.
BRAF2 and BRAF3 hiPSC lines were generated using episomal-based
vectors as previously described (Okita et al., 2011), with modifica-
tions. One microgram of each plasmid pCXLE-hOCT3/4-shp53-F,
pCXLE-hSK, pCXLE-hUL, and pCXLE-EGFP (Addgene) was mixed
with Resuspension Buffer R (Life Technologies) and added to
fibroblasts. Cells were electroporated using the Neon Transfection
System (Life Technologies), re-plated, and placed at 37C. After
5 days, fibroblasts were plated on MEFs and maintained in hiPSC
medium. Clones were chosen based on morphology and growth.
Pluripotencywas verified by immunofluorescence, gene expression,
southern blot, and teratoma formation or in vitro tri-lineage differ-
entiation assays. Fully characterized retrovirally generated WT
hiPSC lines were separately provided.Human Fetal Heart and Immortalized Dermal Skin
Fibroblast Samples
All samples were obtained according to the ethical guidelines pro-
vided by the institutional review board. Human fetal heart was
dissociated in 1 mg/mL collagenase B (Roche) for 3 hr at 37C
and the centrifuged pellet resuspended in PBS + 0.1% BSA. Human
dermal fibroblasts were immortalized using hTERT lentivirus with
6 mg/mL polybrene. After 2 days, cells were selected with 10 mg/mL
blasticidin. Drug-resistant colonies were maintained in 10 mg/mL
blasticidin and expanded for further use.Southern Blot and Karyotyping
Two micrograms of gDNA from retrovirally generated hiPSCs was
digested with BglII, separated on a 0.8% agarose gel, transferred
to a positively charged nylon membrane, and hybridized with
DIG-labeled human OCT4, SOX2, KLF4, and MYC cDNA probes.
Membranes were washed, blocked, and incubated with anti-DIG-
AP Fab fragments (Roche). Probe-target hybrids were incubated
with chemiluminescent CDP-Star substrates (Roche) and detectedby exposure to X-ray film. For karyotyping, hiPSCs were plated on
Matrigel-coated glass coverslip dishes (MatTek), and karyotyping
was performed as previously described (Carvajal-Vergara et al.,
2010).
In Vitro Three-Germ-Layer Differentiation
hiPSCs generated with episomal vectors were differentiated into
three germ layers in vitro using the d-Stem Tri-lineage Differentia-
tion Kit (MicroStem) according to the manufacturer’s instructions.
hiPSCs were plated onmatrix-coated 96-well plates, and day-1me-
dium was added after 24 hr. Cells were maintained for 3 days
(mesoderm) or 6 days (endoderm, ectoderm) at 37C before fixa-
tion. hiPSCs were stained with provided primary antibodies Bra-
chyury (mesoderm), Sox17 (endoderm), or Sox1 (ectoderm) and
corresponding Alexa Fluor secondary antibody.
Teratomas
Animal procedures were performed in accordance with the Icahn
School of Medicine at Mount Sinai’s Institutional Animal Care
and Use Committee. Cells (1–2 3 106) were injected subcutane-
ously into the right hind leg of immunocompromised NOD-
SCID mice (The Jackson Laboratory). Six to ten weeks after injec-
tion teratomas were excised, fixed in formalin, embedded in
paraffin, sectioned, and stained with H&E by the Histology Service
Core Facility at the Icahn School of Medicine at Mount Sinai.
Histological evaluation was performed using a Nikon TE2000-U
microscope and ACT-1 software.
Mutation Analysis and Sequencing
hiPSC gDNA was purified using the DNeasy Blood & Tissue Kit
(Qiagen). PCR amplification of exons 6 and 15 was performed us-
ing primers listed in Table S2. Bioedit Sequence Alignment Editor
version 7.0.5.3 was used for sequencing analysis.
hiPSC Differentiation
hiPSCs were differentiated as previously described (Carvajal-Ver-
gara et al., 2010) with the following modifications. hiPSCs were
cultured on Matrigel-coated plates for 2 days for feeder depletion.
For generation of EBs, hiPSCs were dissociatedwith 1mg/mL colla-
genase B (Roche) for 15min. Cell clumpswere centrifuged at 2003
g for 2 min, and resuspended to clusters of 50–100 cells in differen-
tiation medium containing StemPro 34 (Life Technologies), 2 mM
L-glutamine (Life Technologies), 4 3 104 M monothioglycerol
(Sigma), 50 mg/mL ascorbic acid (Sigma), and 150 mg/mL trans-
ferrin (Roche). EBsweremaintained in 6-well ultra-low attachment
plates (Corning) at 37C in 5%CO2, 5%O2, and 90%N2. Differen-
tiation medium was supplemented with 10 ng/mL BMP4 (R&D
Systems) (day 0), 10 ng/mL BMP4 (R&D Systems) and 15 ng/mL
Activin A (Peprotech) (day 1), and 1.5 mM IWR-1 (Sigma) (day 4).
After day 8, the medium was changed every 5 days to medium
without supplements. EBs were prepared for cell sorting on day
25 of differentiation.
Flow Cytometry
EBs were dissociated in 1 mg/mL collagenase B (Roche) overnight
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(BioLegend #323807) and 1:250 anti-humanCD90-FITC (BD Phar-
mingen #555595) for 1 hr at 4C in PBS + 10% FBS staining buffer.
Gates were set using appropriate isotype control antibodies (Bio-
legend #400125, BD Pharmingen #MOPC-31C). Sorting was per-
formed on an AriaII cell sorter (BD Biosciences). For determination
of CM purity, dissociated single cells were fixed and stained with
mouse-anti-human cTNT (Thermo Fisher Scientific #MA5-12960)
conjugated to Alexa Fluor 488 in vitro using the Zenon Mouse
IgG Labeling Kit (Life Technologies), according to the manufac-
turer’s instructions. Cells were analyzed on an LSR-II flow cytome-
ter (BD Biosciences). Data were analyzed using FlowJo software,
Version 9.3.2.
Immunocytochemistry
Single cells were cultured on Matrigel-coated tissue culture plates
(Falcon), fixed in 4% paraformaldehyde for 15 min at 25C, and
incubated with primary antibodies anti-human cTNT (1:100,
Thermo Fisher #MA5-12960) and SSEA4 (1:25, Developmental
Studies Hybridoma Bank #MC-813-70) in 0.01% Triton permeabi-
lization buffer overnight at 4C. Secondary antibodies were goat
anti-mouse Alexa Fluor 488 or 594 (1:400, Life Technologies #A-
11001, #A-11032). Cells were stained with DAPI (1:1,000) for
20 min at 25C. Fluorescence was detected on the EVOS FL digital
inverted fluorescent microscope (Life Technologies).
Cellular Size and Sarcomeric Organization
Single cells were analyzed 4 days after sorting. The 2D cellular area
of CMswas determined using ImageJ software bymanual outlining
of single cTNT+ cells. The 3D cellular area was quantified using the
mean fluorescence intensity of the FSC channel in SIRPa+/CD90
cells using FlowJo software, version 9.3.2. Sarcomeric organization
was defined as the presence of a striated pattern of cTNT immuno-
fluorescence in >50% of the cellular area, indicating the develop-
ment of organized contractile filaments. Measurements were
blinded and replicated by several independent observers.
Gene Expression
Total RNA was extracted using TRIzol (Life Technologies) and
RNeasy Plus mini kit (Qiagen). Total RNA was reverse transcribed
using oligo(dT) primers with the Superscript II Synthesis Kit (Life
Technologies). qPCR was performed using Fast SYBR GreenMaster
Mix (Applied Biosystems) according to the manufacturer’s instruc-
tions. Expression levels were calculated using the DDCt method
and normalized to GAPDH. Real-time qPCR was performed on a
StepOne Plus Real-Time PCR System (Applied Biosystems) and
analyzed with the StepOne Software v2.2.2. Primers used in
qPCR assays are listed in Table S2.
Calcium Transient Analysis
Ca2+ transients were recorded from CMs 7 days post sorting. Cells
were loaded with the Ca2+ indicator fluo-3-AM (acetomethoxy
form) at 10 mM for 30min and de-esterified. Cells were superfused
with Tyrode’s solution containing 140 mM NaCl, 5.4 mM KCl,
10 mM HEPES, 1 mM NaH2PO4, 1 mM MgCl2, 2 mM CaCl2, and
5 mM glucose (pH 7.4). Fluorescence was recorded by a confocal
microscope. CMs were paced to steady state at 1 Hz, and tran-
sients recorded at 37C using the line-scan mode of the micro-366 Stem Cell Reports j Vol. 7 j 355–369 j September 13, 2016scope. Irregularity was defined as the percentage of transients
with extra peaks. For SR Ca2+ content, cells were exposed to
20 mM caffeine. Recordings were processed and analyzed using
custom MATLAB scripts.
Immunoblotting
Single cells were plated on Matrigel-coated tissue-culture plates.
hiPSCs were treated with 10 ng/mL EGF for 0, 5, 15, 30, or
60 min at 37C, and purified CMs or FLCs were treated with
10 ng/mL AngII for 0 or 15 min at 37C. Cells were lysed in RIPA
buffer supplemented with protease and phosphatase inhibitors.
Protein concentration was determined with a Pierce BCA Protein
Assay Kit using a BSA standard (Thermo Scientific). Twenty micro-
grams of protein was separated on 4%–20% SDS-PAGE gels and
transferred to polyvinylidene fluoride membranes. Blots were
probed with antibodies to p-ERK1/2 T202/Y204 (#4370), ERK1/2
(#4695), pAKT S473 (#4060), AKT (#4691), and GAPDH (#5174)
(all 1:2000, Cell Signaling Technology) overnight at 4C. Blots
werewashed in PBSwith Tween 20 and incubatedwithhorseradish
peroxidase-coupled secondary antibody for 1 hr at 25C. Blotswere
developed using SuperSignal Extended Duration Chemilumines-
cent Substrate (Thermo Scientific).
TGFb ELISA
Secretion of total and active TGFb into conditioned medium was
quantified using ELISA assays according to the manufacturer’s
instructions (BosterBio). rhTGFb (R&D systems #240-B-002) was
used for the standards. For active TGFb levels, conditioned me-
dium was incubated with 1 N HCl and 1.2 N NaOH/0.5 M HEPES.
Samples and standards were added to TGFbmonoclonal antibody
pre-coated 96-well plates and incubated for 90 min at 37C. Bio-
tinylated antibodies were added and incubated at 37C for 1 hr.
After washing with 0.01 M PBS, ABC working solution was added
and incubated at 37C for 30 min. After washing, TMB color
developing agent was added and the plate incubated at 37C in
the dark for 30 min. TMB stop solution was added and the OD
absorbance at 450 nm was recorded in a microplate reader
(Promega).
Co-culture and Conditioned Media Studies
For co-culture studies, cells were mixed and re-plated on Matrigel-
coated tissue-culture plates at a ratio of 60% FLCs/40% CMs in
basic differentiation medium and fixed after 4 days. For condi-
tioned media studies, 2.5 3 104 purified CMs and 105 purified
FLCs were re-plated separately on Matrigel-coated 24-well tissue-
culture dishes in basic differentiationmedium.GDC-0897 (Selleck-
Chem) or DMSO at 10 mM was added to FLCs for 4 days. Condi-
tioned medium was then collected from FLCs and added to CMs.
Ten micrograms of TGFb-NA (R&D Systems #MAB1835) was
incubated with FLC conditioned medium for 90 min prior to CM
exposure. U0126 (Promega) or DMSO at 5 mM was added directly
to co-cultured cells. After an additional 4 days, CMs were fixed to
analyze cell area and gene expression. Ca2+ transients were
analyzed 5 days after U0126 treatment. For analysis of the
direct effect of TGFb on cell size, purified CMs were plated at
2.5 3 104 cells per well and treated with either 1 ng/mL rhTGFb
or 10 ng/mL TGFb-NA, and cell size was analyzed after 4 days.
Proliferation Analysis
Cells were resuspended in PBS at 106 cells/mL.Onemicroliter of re-
constituted LIVE/DEAD Fixable Blue stain (Life Technologies) was
added to the cells at 25C for 30 min in the dark. Cells were fixed
and stained with 5 mL of Alexa Fluor 647 mouse anti-human Ki-
67 (BD Pharmingen #561126) for 30 min at 25C in the dark and
analyzed on an LSR-II flow cytometer (BD Biosciences).Lentiviral Overexpression
The pSIN-EF2-LIN28-PURO transfer plasmid (Addgene #16580)
was used for lentiviral production. LIN28 coding region was
removed by restriction enzyme digestion and replaced with BRAF
T599R cDNA or nothing (empty vector). Packaging plasmid
pCMV-dR8.2-dvpr (Addgene #8455) and envelope plasmid
pCMV-VSV-G (Addgene #8454) were used for subsequent viral pro-
duction. HEK293T cells were transfected with transfer, packaging,
and envelope plasmids using the Superfect Transfection Reagent
(Qiagen), and maintained at 37C. At 48 and 72 hr post transfec-
tion, medium containing viral particles was collected and used
for two rounds of infection of WT1 and WT2 iPSC lines. Clones
were selected by puromycin resistance and verified for viral inte-
gration via PCR, Sanger sequencing, and qPCR for overexpression
of BRAF.Statistics
The t test was used for single comparisons. One-way ANOVA was
used for multiple comparisons, with individual differences
analyzed by Tukey’s or Dunnett’s post test. p Values <0.05 were
considered statistically significant. The number of asterisks indi-
cates the significance level: *p < 0.05, **p < 0.01, ***p < 0.001,
and ****p < 0.0001. Data are presented as means ± SEM. Box-and-
whisker plots show the median to the first and third quartiles
and the minimum and maximum values.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, seven figures, and two tables and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
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